News & Views

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by AFMPS for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enables healthcare providers in Belgium to offer PSMA-PET imaging using a clinically validated gallium-based radiopharmaceutical.

Telix today announces it has launched a novel PET radiochemistry solution based on 18F-aluminium fluoride (AlF), named AlFluorTM.

Telix today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24.

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Greek EOF for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer - a broad clinical label. This approval enhances the options available to healthcare providers across Greece for PSMA-PET imaging using a clinically-validated, gallium-based radiopharmaceutical. 

Telix today announces that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is now commercially available nationally in the United States (U.S.).

Telix today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Germany by BfArM[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enhances the options available to healthcare providers across Germany for PSMA-PET[3] imaging, and will ensure more patients can access this essential diagnostic tool.

Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Portugal by INFARMED for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enhances the options available to healthcare providers across Portugal for PSMA-PET imaging using a clinically validated gallium-based radiopharmaceutical.